Cubist Pharmaceuticals Inc CBST +35% - Shares are sharply higher as Merck announced plans to acquire Cubist for $102 per share.
Acceleron Pharma Inc XLRN+20 - The company reported positive preliminary data from its luspatercept phase 2 clinical trial.
Calithera Biosciences Inc CALA +18% - The rise in share price may be a result of the Cubist/Merck deal as the company is only valued at $206 million and in the same industry at Cubist.
Cempra Inc CEMP +8% - Shares are also trending higher amid the Merck/Cubist deal.
Isis Pharmaceuticals, Inc. ISIS +8% - On Sunday, the company reported positive phase 2 results from its study of ISIS-FXIRx. In addition, analysts at Stifel Nicolaus maintained the Buy rating and raised the price target to $65.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.